Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, is pleased to announce the grant of patent number EP3317301 entitled “Combination therapies comprising antibody molecules to LAG-3” by the European Patent Office.

See more here:

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh